A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y 12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE-PCI trial

Circulation: Cardiovascular Interventions

Volumn 5, Issue 3, 2012, Pages 336-346

  Welsh, Robert C ^a   Rao, Sunil V ^b   Zeymer, Uwe ^c   Thompson, Vivian P ^b   Huber, Kurt ^d   Kochman, Janusz ^e   McClure, Matthew W ^f   Gretler, Daniel D ^f   Bhatt, Deepak L ^g   Gibson, C Michael ^h   Angiolillo, Dominick J ⁱ   Gurbel, Paul A ^j   Berdan, Lisa G ^b   Paynter, Gayle ^b   Leonardi, Sergio ^b,k   Madan, Mina ^l   French, William J ^m   Harrington, Robert A ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Institut fur Herzinfarktforschung   (Germany)

^d Cardiology and Emergency Medicine   (Austria)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f Portola Pharmaceuticals Inc   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^j SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^k FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^l UNIVERSITY OF TORONTO   (Canada)

^m Methodist Hospital California   (United States)

more..

Author keywords

Antiplatelets; Cardiovascular pharmacology; Catheter based coronary interventions; Chronic ischemic heart disease; Platelet function inhibitors

Indexed keywords

CLOPIDOGREL; ELINOGREL; HEART ENZYME; PLACEBO;

ADULT; ANGINA PECTORIS; ARTICLE; BACKACHE; BLEEDING; BLOOD CLOT LYSIS; BRADYCARDIA; CARDIOVASCULAR RISK; CONSTIPATION; CONTROLLED STUDY; CYST; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EPISTAXIS; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; INFECTION; INSOMNIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACTIVATION; MUSCLE SPASM; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE;

ADMINISTRATION, ORAL; ANGIOPLASTY, BALLOON, CORONARY; CANADA; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEART DISEASES; HEMORRHAGE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUINAZOLINONES; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; STROKE; SULFONAMIDES; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84864617340     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.964197     Document Type: Article

References (19)

1. American College of Cardiology; American Heart Association Task Force on Practice Guidelines. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv. 2008;71:E1-E40.
2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
3. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lamas GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC, Jr., Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296-329.
4. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-2306.
5. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930-942.
6. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De SS, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357: 2001-2015.
8. Pena A, Collet JP, Hulot JS, Silvain J, Barthelemy O, Beygui F, Funck-Brentano C, Montalescot G. Can we override clopidogrel resistance? Circulation. 2009;119:2854-2857.
9. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004;109:3064-3067.
10. Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: a need for novel strategies. Mol Biosyst. 2010;6:305-315.
11. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
12. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J. 2003;145: 239-247.
13. Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 2010;6: 445-453.
14. Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010;160:65-72.
15. Lancaster HO. Significance Tests in Discrete Distributions. J Am Stat Assoc. 1961;56;223-234.
16. Andre P, Deguzman F, Haberstock-Debic H, Mills S, Pak Y, Inagaki M, Pandey A, Hollenbach S, Phillips DR, Conley PB. Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding. J Pharmacol Exp Ther. 2011;338:22-30.
17. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361: 2330-2341.
18. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361:2318-29.
19. Thel MC, Califf RM, Tardiff BE, Gardner LH, Sigmon KN, Lincoff AM, Topol EJ, Kitt MM, Blankenship JC, Tcheng JE. Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol. 2000;85:427-434.